Disease · MONDO_0005313
Targets30
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 20 of 30
Download this page as JSON| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 8 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| PTGS1 | Cyclooxygenase | 3 | Cyclooxygenase inhibitor | Phase 2 | https://conductscience.org/library/genes/5742 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 3 | Cyclooxygenase inhibitor | Phase 2 | https://conductscience.org/library/genes/5743 | Drugs and targets |
| ADORA2A | Adenosine A2 receptor | 1 | Adenosine A2 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/135 | Drugs and targets |
| ADORA2B | Adenosine A2 receptor | 1 | Adenosine A2 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/136 | Drugs and targets |
| FAAH | Fatty-acid amide hydrolase 1 | 1 | Anandamide amidohydrolase inhibitor | Phase 2 | https://conductscience.org/library/genes/2166 | Drugs and targets |
| PDE10A | 3',5'-cyclic phosphodiesterase | 1 | 3',5'-cyclic phosphodiesterase inhibitor | Phase 3 | https://conductscience.org/library/genes/10846 | Drugs and targets |
| PDE1A | 3',5'-cyclic phosphodiesterase | 1 | 3',5'-cyclic phosphodiesterase inhibitor | Phase 3 | https://conductscience.org/library/genes/5136 | Drugs and targets |
| PDE1B | 3',5'-cyclic phosphodiesterase | 1 | 3',5'-cyclic phosphodiesterase inhibitor | Phase 3 | https://conductscience.org/library/genes/5153 | Drugs and targets |
| PDE1C | 3',5'-cyclic phosphodiesterase | 1 | 3',5'-cyclic phosphodiesterase inhibitor | Phase 3 | https://conductscience.org/library/genes/5137 | Drugs and targets |
| PDE2A | 3',5'-cyclic phosphodiesterase | 1 | 3',5'-cyclic phosphodiesterase inhibitor | Phase 3 | https://conductscience.org/library/genes/5138 | Drugs and targets |
| PDE3A | 3',5'-cyclic phosphodiesterase | 1 | 3',5'-cyclic phosphodiesterase inhibitor | Phase 3 | https://conductscience.org/library/genes/5139 | Drugs and targets |
| PDE3B | 3',5'-cyclic phosphodiesterase | 1 | 3',5'-cyclic phosphodiesterase inhibitor | Phase 3 | https://conductscience.org/library/genes/5140 | Drugs and targets |
| PDE4A | 3',5'-cyclic phosphodiesterase | 1 | 3',5'-cyclic phosphodiesterase inhibitor | Phase 3 | https://conductscience.org/library/genes/5141 | Drugs and targets |
| PDE4B | 3',5'-cyclic phosphodiesterase | 1 | 3',5'-cyclic phosphodiesterase inhibitor | Phase 3 | https://conductscience.org/library/genes/5142 | Drugs and targets |
| PDE4C | 3',5'-cyclic phosphodiesterase | 1 | 3',5'-cyclic phosphodiesterase inhibitor | Phase 3 | https://conductscience.org/library/genes/5143 | Drugs and targets |
| PDE4D | 3',5'-cyclic phosphodiesterase | 1 | 3',5'-cyclic phosphodiesterase inhibitor | Phase 3 | https://conductscience.org/library/genes/5144 | Drugs and targets |
| PDE5A | 3',5'-cyclic phosphodiesterase | 1 | 3',5'-cyclic phosphodiesterase inhibitor | Phase 3 | https://conductscience.org/library/genes/8654 | Drugs and targets |
| PDE6A | 3',5'-cyclic phosphodiesterase | 1 | 3',5'-cyclic phosphodiesterase inhibitor | Phase 3 | https://conductscience.org/library/genes/5145 | Drugs and targets |
| PDE6B | 3',5'-cyclic phosphodiesterase | 1 | 3',5'-cyclic phosphodiesterase inhibitor | Phase 3 | https://conductscience.org/library/genes/5158 | Drugs and targets |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005313/targets